Pricing Log in Create free account

Lyra Therapeutics, Inc. (LYRA) vs Scinai Immunotherapeutics Ltd. Sponsored ADR (SCNI)

Lyra Therapeutics, Inc. and Scinai Immunotherapeutics Ltd. Sponsored ADR are both Biotechnology companies. Lyra Therapeutics, Inc. is the larger, with a market value of $870.0K against $640.0K — 1.4× the size. Lyra Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Scinai Immunotherapeutics Ltd. Sponsored ADR trades at 0.0×. Scinai Immunotherapeutics Ltd. Sponsored ADR has the higher net margin (0.00% vs −7,266.1%) and the higher return on invested capital (0.00% vs 0.00%). Across the 13 metrics below, Scinai Immunotherapeutics Ltd. Sponsored ADR leads on 9 and Lyra Therapeutics, Inc. on 4.

Valuation

Metric LYRA SCNI Biotechnology median
P/E n/m 0.01 8.50
P/S 0.74 n/m 9.71
P/B n/m 0.05 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA 0.51 0.28 0.64
EV/Sales (39.19) n/m 9.21
Earnings yield (10,078.95%) 11,368.55% (33.15%)
Free cash flow yield (9,793.95%) (2,331.48%) (25.50%)

Profitability

Metric LYRA SCNI Biotechnology median
Gross margin 100.00% 0.00% 65.16%
Operating margin (7,794.47%) 0.00% 0.00%
Net margin (7,266.08%) 0.00% 0.00%
Free cash flow margin (7,261.06%) 0.00% 0.00%
Return on equity (6,594.98%) 0.00% (56.36%)
Return on assets (56.45%) 0.00% (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric LYRA SCNI Biotechnology median
Revenue growth (TTM) (74.05%) — 6.02%
EPS growth (last fiscal year) 73.96% (159.83%) 30.26%
Revenue growth, 5-year CAGR (20.38%) — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric LYRA SCNI Biotechnology median
Debt to equity 0.00 0.02 0.00
Current ratio 1.71 1.56 4.72
Net debt to EBITDA 0.52 0.25 0.96

Dividend

Metric LYRA SCNI Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric LYRA SCNI Biotechnology median
Market cap 870.00k 640.00k 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack